Manufacturing and preparing experimental anti-cancer drugs for clinical trials in the UK

The Cancer Research UK Formulation Unit is one of a kind and is based within the Strathclyde Institute for Pharmacy & Biomedical Sciences.

About the Cancer Research UK Formulation Unit 

The facility was first established at Strathclyde in 1983 and can take a new drug, develop it, manufacture it and progress it through the process to supply it directly to clinic trial.

Several of our compounds have been passed to international pharmaceutical companies for further development, and some are now available worldwide for the treatment of cancer. For example, temozolomide and abiraterone acetate have been provided to over 4 million cancer patients.

Licenses

The Unit has a Good Manufacturing Practice (GMP) license with an (MA) IMP licence for the production of Investigational Medicinal Products granted by the MHRA.

Facilities

The facility has dedicated cleanroom manufacturing facilities supported by analytical laboratories. The Unit applies a full range of pharmaceutical research and development tools to each project handled.

Our expertise

Expertise includes drug characterisation, formulation development and regulatory requirements.